Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi
BioPharma Dive
Mon, 01/8/24 - 10:22 pm
Biogen
Pharma CEOs
Chris Viehbacher
Leqembi
Alzheimer's disease
insurance
JPMHC 2024
Europe revokes marketing authorization for generic versions of Biogen's MS drug
Reuters
Tue, 12/19/23 - 10:08 am
Biogen
Tecfidera
MS
multiple sclerosis
Europe
generics
As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches
Fierce Pharma
Wed, 11/8/23 - 12:10 pm
Biogen
Pharma CEOs
Chris Viehbacher
earnings
Leqembi
Skyclarys
Biogen's M&A, Alzheimer's drug launch costs spark profit forecast cut
Reuters
Wed, 11/8/23 - 11:35 am
Biogen
Alzheimer's disease
Leqembi
Reata
M&A
earnings
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
Reuters
Tue, 11/7/23 - 09:55 am
Biogen
SAGE Therapeutics
postpartum depression
drug pricing
Zurzuvae
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 10/25/23 - 10:42 pm
Eisai
Biogen
Leqembi
Alzheimer's disease
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Reuters
Mon, 10/23/23 - 05:11 pm
Roche
legal
Biogen
biosimilars
Actemra
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Stat
Fri, 10/20/23 - 09:57 am
Biogen
Christopher Viehbacher
Pharma CEOs
risk
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
Fierce Biotech
Mon, 10/16/23 - 10:12 am
Alzheimer's disease
Biogen
Eisai
Eli Lilly
Leqembi
donanemab
Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit
Fierce Pharma
Thu, 10/12/23 - 05:18 pm
Biogen
Aduhelm
legal
Eisai
Alzheimer's disease
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra
Fierce Pharma
Mon, 10/2/23 - 11:48 am
Biogen
Roche
Actemra
autoimmune disease
biosimilars
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Reuters
Tue, 09/26/23 - 10:23 am
Biogen
Eisai
Japan
Leqembi
Alzheimer's disease
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Mon, 09/11/23 - 12:34 pm
Alzheimer's disease
Eli Lilly
Biogen
Eisai
Leqembi
donanemab
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Fierce Biotech
Thu, 08/31/23 - 11:54 am
SAGE Therapeutics
layoffs
Biogen
major depressive disorcer
zuranolone
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
BioSpace
Fri, 08/25/23 - 09:53 am
Biogen
Sandoz
FDA
biosimilars
MS
multiple sclerosis
Tysabri
Brii Biosciences aims to come up big where Sage and Biogen fell short
Pharma Voice
Mon, 08/21/23 - 06:53 pm
Brii Biosciences
depression
SAGE Therapeutics
Biogen
BRII-296
postpartum depression
Biogen kicks off 1,000 layoffs as part of CEO Viehbacher’s ‘complete redesign’
Fierce Pharma
Fri, 08/18/23 - 11:40 am
Biogen
layoffs
restructuring
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
Fierce Pharma
Tue, 08/15/23 - 11:53 am
Biogen
Reata Pharmaceuticals
M&A
Skyclarys
Friedreich’s ataxia
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »